These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6461800)

  • 1. Nuclear androgen receptor as marker of responsiveness to medroxyprogesterone acetate in human renal cell carcinoma.
    Concolino G; Marocchi A; Toscano V; Di Silverio F
    J Steroid Biochem; 1981 Dec; 15():397-402. PubMed ID: 6461800
    [No Abstract]   [Full Text] [Related]  

  • 2. Steroid hormone receptors in normal and malignant human renal tissue: relationship with progestin therapy.
    Ronchi E; Pizzocaro G; Miodini P; Piva L; Salvioni R; Di Fronzo G
    J Steroid Biochem; 1984 Sep; 21(3):329-35. PubMed ID: 6238209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fundamental study of endocrine therapy for renal cell carcinoma--progesterone and androgen receptors in normal kidneys and renal cell carcinomas (author's transl)].
    Nakano E
    Nihon Hinyokika Gakkai Zasshi; 1980 Jul; 71(7):775-87. PubMed ID: 7420805
    [No Abstract]   [Full Text] [Related]  

  • 4. Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy.
    Nakano E; Tada Y; Fujioka H; Matsuda M; Osafune M; Kotake T; Sato B; Takaha M; Sonoda T
    J Urol; 1984 Aug; 132(2):240-5. PubMed ID: 6330380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.
    Tomic R; Ljungberg B; Damber JE
    Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122
    [No Abstract]   [Full Text] [Related]  

  • 6. Hormonal therapy of renal cell carcinoma (RCC).
    Bracci U; DiSilverio F; Concolino G
    Prog Clin Biol Res; 1982; 100():623-40. PubMed ID: 7145993
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma.
    Kjaer M
    Cancer Treat Rev; 1988 Sep; 15(3):195-209. PubMed ID: 2974757
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase II study.
    Kjaer M; Frederiksen PL
    Cancer Treat Rep; 1986 Mar; 70(3):431-2. PubMed ID: 2937534
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjunctive medroxyprogesterone acetate to radical nephrectomy in category M0 renal cell carcinoma. Preliminary report of a prospective randomized trial.
    Pizzocaro G; Di Fronzo G; Piva L; Salvioni R; Ronchi E; Cappelletti V; Giongo A; Mastroberardino E; Cozzoli C; Dormia E; Minervini S; Zanollo A; Fontanella U; Giannoni R; Maggioni A; Lasio E
    Eur Urol; 1983; 9(4):202-6. PubMed ID: 6223819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of medroxyprogesterone acetate with cytosol androgen receptors in the rat hypothalamus and pituitary.
    Pérez-Palacios G; Chávez B; Vilchis F; Escobar N; Larrea F; Pérez AE
    J Steroid Biochem; 1983 Dec; 19(6):1729-35. PubMed ID: 6231415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific androgen binding in the kidney and estrogen-dependent renal carcinoma of the Syrian hamster.
    Li JJ; Cuthbertson TL; Li SA
    Endocrinology; 1977 Oct; 101(4):1006-15. PubMed ID: 908261
    [No Abstract]   [Full Text] [Related]  

  • 12. Calcification of humeral metastasis of renal adenocarcinoma 8 months after medroxyprogesterone acetate therapy.
    Scanni A; Riundi R; Vezzoni MA; Canigiula L
    J Urol; 1984 May; 131(5):984. PubMed ID: 6231386
    [No Abstract]   [Full Text] [Related]  

  • 13. Scintigraphic evidence for the regression of skeletal metastases from a hypernephroma following long-term treatment with medroxyprogesterone acetate.
    Minervini R; Fiorentini L; Carlino F; Mazzuca N; Mariani G
    J Nucl Med Allied Sci; 1982; 26(1):55-9. PubMed ID: 6213743
    [No Abstract]   [Full Text] [Related]  

  • 14. Androgenic, antiandrogenic, and synandrogenic actions of progestins: role of steric and allosteric interactions with androgen receptors.
    Bullock LP; Bardin CW; Sherman MR
    Endocrinology; 1978 Nov; 103(5):1768-82. PubMed ID: 748017
    [No Abstract]   [Full Text] [Related]  

  • 15. Medroxyprogesterone acetate: receptor binding and correlated effects on steroidogenesis in rat granulosa cells.
    Pridjian G; Schmit V; Schreiber J
    J Steroid Biochem; 1987 Mar; 26(3):313-9. PubMed ID: 2953940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Deoxyribonucleic acid content and medroxyprogesterone acetate treatment in metastatic renal cell carcinoma.
    Neuwirth H; Blyth B; Richie AW; Taube DM; deKernion JB
    J Urol; 1990 Sep; 144(3):749-50. PubMed ID: 2143789
    [No Abstract]   [Full Text] [Related]  

  • 17. Nuclear retention of all steroid hormone receptor classes in the hamster renal carcinoma.
    Li JJ; Li SA; Cuthbertson TL
    Cancer Res; 1979 Jul; 39(7 Pt 1):2647-51. PubMed ID: 445467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen, progesterone, and androgen-binding sites in renal cell carcinoma. Observations obtained in Phase II trial of flutamide.
    Ahmed T; Benedetto P; Yagoda A; Watson RC; Scher HI; Herr HW; Sogani PC; Whitmore WF; Pertschuk L
    Cancer; 1984 Aug; 54(3):477-81. PubMed ID: 6733677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of high dose medroxyprogesterone acetate treatment on antithrombin III and other plasma proteins in males with renal cell or prostatic carcinoma.
    Nilsson TK; Tomic R; Ljungberg B
    Scand J Urol Nephrol; 1989; 23(1):11-4. PubMed ID: 2522237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate.
    Quinn MA; Cauchi M; Fortune D
    Gynecol Oncol; 1985 Jul; 21(3):314-9. PubMed ID: 3159630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.